{"id":7787,"date":"2013-06-18T03:57:22","date_gmt":"2013-06-18T07:57:22","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=7787"},"modified":"2013-06-18T03:57:22","modified_gmt":"2013-06-18T07:57:22","slug":"medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787","title":{"rendered":"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/18\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Medivation Inc (NASDAQ:MDVN) had declined by 6.78 percent to close at $47.41 per share for the end of last trading session on Monday. The shares of the company had been trading in the range of $45.47 to $48.50 per share for the day, after opening at $48.03 per share. The shares of Medivation Inc (NASDAQ:MDVN) had recorded 52 week low price level at $40.81 per share and 52 week high price level at $59.24 per share.<\/p>\n<p style=\"text-align: justify;\">Medivation Inc (NASDAQ:MDVN) is primarily focused on the development and commercialization of novel therapies with its advanced program XTANDI capsules being carried out in partnership with Astellas Pharma Inc. Further, this partnership is also extended for conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer.<\/p>\n<p style=\"text-align: justify;\">The shares of Medivation Inc (NASDAQ:MDVN) had recently been trading at lower prices with very heavy trading volumes, which had made the bio pharmaceutical company to be added into the Growing Stock Reports\u2019 NASDAQ decliners watch list. The company had witnessed the trade of 5.38 million shares on Monday, which is relatively higher compared to the average trading volume at 986,336 shares per day.<\/p>\n<p style=\"text-align: justify;\">Medivation Inc (NASDAQ:MDVN) presently holds 74.98 million shares outstanding in the market with an institutional ownership of 97 percent of its holdings. The shares of the company are presently trading near their 52 week low price levels which had sent a cautious sentiment to the investors.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/18\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Medivation Inc (NASDAQ:MDVN) had declined by 6.78 percent to close at $47.41 per share for the end [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":41700,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[2694,2695],"stock_ticker":[],"class_list":["post-7787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-medivation-inc-nasdaqmdvn","tag-nasdaqmdvn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/18\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Medivation Inc (NASDAQ:MDVN) had declined by 6.78 percent to close at $47.41 per share for the end [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-18T07:57:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1100\" \/>\n\t<meta property=\"og:image:height\" content=\"619\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules\",\"datePublished\":\"2013-06-18T07:57:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg\",\"keywords\":[\"Medivation Inc (NASDAQ:MDVN)\",\"NASDAQ:MDVN\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\",\"name\":\"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg\",\"datePublished\":\"2013-06-18T07:57:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg\",\"width\":1100,\"height\":619,\"caption\":\"NEW YORK, NY - JANUARY 3: The day's numbers for the Dow Jones Industrial Average are displayed on a screen at the at the Nasdaq MarketSite in Times Square, January 3, 2019 in New York City. U.S. stocks dropped again on Thursday after Apple warned that its first-quarter sales would be less than expected. (Photo by Drew Angerer\/Getty Images)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787","og_locale":"en_US","og_type":"article","og_title":"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules  - Wall Street PR","og_description":"Boston, MA 06\/18\/2013 (wallstreetpr) &#8211;\u00a0The share prices of Medivation Inc (NASDAQ:MDVN) had declined by 6.78 percent to close at $47.41 per share for the end [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-06-18T07:57:22+00:00","og_image":[{"width":1100,"height":619,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules","datePublished":"2013-06-18T07:57:22+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg","keywords":["Medivation Inc (NASDAQ:MDVN)","NASDAQ:MDVN"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787","url":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787","name":"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg","datePublished":"2013-06-18T07:57:22+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet6.jpg","width":1100,"height":619,"caption":"NEW YORK, NY - JANUARY 3: The day's numbers for the Dow Jones Industrial Average are displayed on a screen at the at the Nasdaq MarketSite in Times Square, January 3, 2019 in New York City. U.S. stocks dropped again on Thursday after Apple warned that its first-quarter sales would be less than expected. (Photo by Drew Angerer\/Getty Images)"},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/medivation-inc-nasdaqmdvn-focus-on-novel-therapies-with-its-advanced-program-xtandi-capsules-7787#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Medivation Inc (NASDAQ:MDVN) focus on novel therapies with its advanced program XTANDI capsules"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=7787"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/7787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/41700"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=7787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=7787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=7787"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=7787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}